Compare Stocks: RENB, DSGN, CLYM, and OLMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$17.28 +1.5%	$13.35	$1.54 ▼ $18.14	$977.57M	0.08	1.18 million shs	957,409 shs
DSGN Design Therapeutics	$14.99 -3.7%	$13.59	$4.92 ▼ $17.25	$973.77M	1.63	478,463 shs	551,777 shs
OLMA Olema Pharmaceuticals	$10.69 -1.9%	$11.33	$5.36 ▼ $36.26	$953.72M	2.03	1.05 million shs	748,503 shs
RENB Lunai Bioworks	$1.54 +21.7%	$1.69	$0.12 ▼ $1.43	$250.24M	0.54	2.93 million shs	880,400 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	+1.53%	+5.82%	+37.36%	+57.09%	+668.00%
DSGN Design Therapeutics	-3.66%	+1.08%	+27.25%	+36.65%	+212.94%
OLMA Olema Pharmaceuticals	-1.93%	+0.56%	-6.96%	-21.86%	+96.15%
RENB Lunai Bioworks	0.00%	0.00%	0.00%	0.00%	-33.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$17.28 +1.5%	$13.35	$1.54 ▼ $18.14	$977.57M	0.08	1.18 million shs	957,409 shs
DSGN Design Therapeutics	$14.99 -3.7%	$13.59	$4.92 ▼ $17.25	$973.77M	1.63	478,463 shs	551,777 shs
OLMA Olema Pharmaceuticals	$10.69 -1.9%	$11.33	$5.36 ▼ $36.26	$953.72M	2.03	1.05 million shs	748,503 shs
RENB Lunai Bioworks	$1.54 +21.7%	$1.69	$0.12 ▼ $1.43	$250.24M	0.54	2.93 million shs	880,400 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	+1.53%	+5.82%	+37.36%	+57.09%	+668.00%
DSGN Design Therapeutics	-3.66%	+1.08%	+27.25%	+36.65%	+212.94%
OLMA Olema Pharmaceuticals	-1.93%	+0.56%	-6.96%	-21.86%	+96.15%
RENB Lunai Bioworks	0.00%	0.00%	0.00%	0.00%	-33.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.00	Buy	$22.75	31.66% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	10.07% Upside
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	296.63% Upside
RENB Lunai Bioworks	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RENB, DSGN, CLYM, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/7/2026	CLYM Climb Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
7/27/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$17.00 ➝ $20.00
7/17/2026	CLYM Climb Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$4.92 per share	N/A
RENB Lunai Bioworks	N/A	N/A	N/A	N/A	$0.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/5/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
RENB Lunai Bioworks	-$88.43M	-$0.77	N/A	N/A	N/A	N/A	-60.38%	-47.04%	N/A

Latest RENB, DSGN, CLYM, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RENB Lunai Bioworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	31.45	31.45
DSGN Design Therapeutics	N/A	18.86	18.86
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
RENB Lunai Bioworks	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
DSGN Design Therapeutics	56.64%
OLMA Olema Pharmaceuticals	91.78%
RENB Lunai Bioworks	71.41%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	2.60%
DSGN Design Therapeutics	17.10%
OLMA Olema Pharmaceuticals	12.56%
RENB Lunai Bioworks	0.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable
RENB Lunai Bioworks	20	162.39 million	171.26 million	Optionable

RENB, DSGN, CLYM, and OLMA Headlines

Recent News About These Companies

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

June 16, 2026 | benzinga.com

Lunai Bioworks Furloughs Staff Amid Liquidity Constraints

March 5, 2026 | tipranks.com

Lunai Bioworks Faces Nasdaq Delisting, Hearing Scheduled

February 23, 2026 | tipranks.com

Lunai Bioworks Secures $3.1M in Private Placement

November 25, 2025 | tipranks.com

Lunai Bioworks announces early results from AI-based platform

October 31, 2025 | msn.com

Lunai Bioworks unveils new corporate identity

September 30, 2025 | msn.com

Lunai Bioworks advances biomarker discovery preclinical program in Parkinson’s

September 25, 2025 | msn.com

Lunai Bioworks Inc.: Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

September 25, 2025 | finanznachrichten.de

Lunai Bioworks Inc.: Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

September 25, 2025 | finanznachrichten.de

Lunai Bioworks to implement 10:1 reverse stock split

September 25, 2025 | msn.com

Renovaro Biosciences Announces Reverse Stock Split

September 25, 2025 | msn.com

Lunai Bioworks stock plunges after announcing 10:1 reverse split

September 25, 2025 | za.investing.com

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

September 25, 2025 | accessnewswire.comA

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

September 24, 2025 | accessnewswire.comA

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

September 11, 2025 | accessnewswire.comA

Renovaro Inc.: Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

September 9, 2025 | finanznachrichten.de

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

September 9, 2025 | accessnewswire.comA

Lunai Bioworks Strengthens European Strategy Through Restructuring

September 8, 2025 | accessnewswire.comA

Renovaro BioSciences retains American Defense International

September 4, 2025 | msn.com

Lunai Bioworks Inc. Retains American Defense International

September 4, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

RENB, DSGN, CLYM, and OLMA Company Descriptions

Climb Bio NASDAQ:CLYM

$17.28 +0.26 (+1.53%)

As of 08/21/2026 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Design Therapeutics NASDAQ:DSGN

$14.99 -0.57 (-3.66%)

As of 08/21/2026 04:00 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Olema Pharmaceuticals NASDAQ:OLMA

$10.69 -0.21 (-1.93%)

As of 08/21/2026 04:00 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Lunai Bioworks NASDAQ:RENB

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RENB, DSGN, CLYM, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RENB, DSGN, CLYM, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RENB, DSGN, CLYM, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RENB, DSGN, CLYM, and OLMA Company Descriptions

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Lunai Bioworks NASDAQ:RENB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RENB, DSGN, CLYM, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RENB, DSGN, CLYM, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RENB, DSGN, CLYM, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RENB, DSGN, CLYM, and OLMA Company Descriptions

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Lunai Bioworks NASDAQ:RENB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools